sararwut-jaimassiri-shutterstock-com-crispr-
Sararwut Jaimassiri / Shutterstock.com
11 March 2016Americas

Let CRISPR/Cas9 battle commence

The US Patent and Trademark Office (USPTO) has opened proceedings to determine who owns the rights to the CRISPR/Cas9 technology.

The USPTO kick-started an interference proceeding yesterday, March 10, between the Broad Institute of Massachusetts Institute of Technology and Harvard and the University of California.

The dispute will determine which party is the owner of the US patent rights to the gene-editing technology.

Interference proceedings are initiated when two parties file claims to the ownership of an invention. The proceeding was confirmed on January 11.

CRISPR/Cas9 technology comprises two parts: an RNA molecule that recognises and targets viruses, and the protein element, which uses enzymes to cut through the DNA sequence.

The technology has the potential to be used to correct defective genetic sequences in humans and has its basis in naturally occurring bacterial immune systems in humans.

LSIPR has published several articles on the CRISPR patent dispute. You can see some of them below:

USPTO ignites CRISPR/Cas9 patent battle

CRISPR: the shifting sands of patentability

Are the Broad Institute's CRISPR patents too broad?

The CRISPR patent war

CRISPR: careless talk costs patents

Why CRISPR may define pre- and post-AIA changes

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
13 January 2016   Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.
Europe
29 October 2015   Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.
Americas
14 April 2016   Regeneron Pharmaceuticals has agreed a licensing deal that it says will enable it to advance CRISPR/Cas gene-editing technology.

More on this story

Americas
13 January 2016   Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.
Europe
29 October 2015   Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.
Americas
14 April 2016   Regeneron Pharmaceuticals has agreed a licensing deal that it says will enable it to advance CRISPR/Cas gene-editing technology.

More on this story

Americas
13 January 2016   Scientists from two US universities will fight out the ownership of the intellectual property rights to the CRISPR/Cas9 technology after the US Patent and Trademark Office agreed to initiate an interference proceeding.
Europe
29 October 2015   Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.
Americas
14 April 2016   Regeneron Pharmaceuticals has agreed a licensing deal that it says will enable it to advance CRISPR/Cas gene-editing technology.